FATE FATE THERAPEUTICS INC
Nasdaq · SEC CIK 1434316 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $322.8K 6 sales by 2 insiders
- Filings on record
- 170 since 2021-07-02, latest 2026-08-05 16:03
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Valamehr Bahram | Pres, CEO, Dir | — | $168.1K |
| TAHL CINDY | See Remarks | — | $154.7K |
| Adawi Kamal | CFO | — | — |
| Redmile Group, LLC | Dir, 10% | — | — |
| EPSTEIN ROBERT S | Dir | — | — |
| RASTETTER WILLIAM H | Dir | — | — |
Transactions 145
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-27 | 2022-01-25 | FATE | Plavsic Mark | Chief Technical Off | A - Grant | $0.00 | +33.3K | 130.8K | +34% | $0 |
| D | 2022-01-27 | 2022-01-25 | FATE | Dulac Edward J III | CFO | A - Grant | $0.00 | +33.3K | 141.9K | +31% | $0 |
| D | 2022-01-27 | 2022-01-25 | FATE | Chu Yu-Waye | Chief Medical Off | A - Grant | $0.00 | +33.3K | 155.1K | +27% | $0 |
| DM | 2022-01-24 | 2022-01-20+ | FATE | Wolchko J Scott | Pres, CEO, Dir | S - Sale+OE | $39.66 | -40.0K | 431.5K | -8% | -$1.59M |
| DM | 2022-01-24 | 2022-01-20+ | FATE | Wolchko J Scott | Pres, CEO, Dir | M - OptEx | $2.72 | +40.0K | 461.5K | +9% | +$108.9K |
| M | 2022-01-13 | 2022-01-11 | FATE | Valamehr Bahram | Chief R, D Off | S - Sale | $48.50 | -4,570 | 146.5K | -3% | -$221.7K |
| M | 2022-01-13 | 2022-01-11 | FATE | Chu Yu-Waye | Senior VP Clinical Development | S - Sale | $48.51 | -3,965 | 121.8K | -3% | -$192.3K |
| M | 2022-01-13 | 2022-01-11 | FATE | Dulac Edward J III | CFO | S - Sale | $48.45 | -1,770 | 108.6K | -2% | -$85.8K |
| M | 2022-01-13 | 2022-01-11 | FATE | TAHL CINDY | GC, Sec | S - Sale | $48.53 | -5,419 | 155.8K | -3% | -$263.0K |
| M | 2022-01-13 | 2022-01-11 | FATE | Wolchko J Scott | Pres, CEO, Dir | S - Sale | $48.68 | -14.6K | 431.5K | -3% | -$709.0K |
| M | 2022-01-12 | 2022-01-10 | FATE | TAHL CINDY | GC, Sec | S - Sale | $46.43 | -7,738 | 161.9K | -5% | -$359.3K |
| M | 2022-01-12 | 2022-01-10 | FATE | Wolchko J Scott | Pres, CEO, Dir | S - Sale | $46.86 | -34.2K | 446.1K | -7% | -$1.60M |
| M | 2022-01-12 | 2022-01-10 | FATE | Valamehr Bahram | Chief R, D Off | S - Sale | $46.38 | -5,596 | 151.5K | -4% | -$259.6K |
| DM | 2022-01-04 | 2022-01-03 | FATE | TAHL CINDY | GC, Sec | S - Sale+OE | $59.34 | -50.0K | 214.6K | -19% | -$2.97M |
| D | 2022-01-04 | 2022-01-03 | FATE | TAHL CINDY | GC, Sec | M - OptEx | $6.55 | +50.0K | 219.0K | +30% | +$327.5K |
| D | 2021-12-21 | 2021-12-20 | FATE | Dulac Edward J III | CFO | M - OptEx | $35.52 | +14.4K | 126.4K | +13% | +$512.8K |
| D | 2021-12-21 | 2021-12-20 | FATE | Dulac Edward J III | CFO | S - Sale+OE | $60.00 | -16.0K | 110.4K | -13% | -$958.6K |
| DM | 2021-12-14 | 2021-12-13 | FATE | Valamehr Bahram | Chief R, D Off | S - Sale+OE | $47.66 | -25.0K | 172.6K | -13% | -$1.19M |
| D | 2021-12-14 | 2021-12-13 | FATE | Valamehr Bahram | Chief R, D Off | M - OptEx | $2.73 | +25.0K | 181.7K | +16% | +$68.2K |
| DM | 2021-12-13 | 2021-12-10 | FATE | Chu Yu-Waye | Senior VP Clinical Development | S - Sale+OE | $51.46 | -7,500 | 130.3K | -5% | -$385.9K |
| D | 2021-12-13 | 2021-12-10 | FATE | Chu Yu-Waye | Senior VP Clinical Development | M - OptEx | $16.32 | +7,500 | 133.3K | +6% | +$122.4K |
| 2021-11-22 | 2021-11-19 | FATE | Dulac Edward J III | CFO | A - Grant | $0.00 | +59.5K | 111.9K | +114% | $0 | |
| 2021-11-22 | 2021-11-19 | FATE | Plavsic Mark | Chief Technical Off | A - Grant | $0.00 | +59.5K | 97.5K | +157% | $0 | |
| 2021-11-22 | 2021-11-19 | FATE | TAHL CINDY | GC, Sec | A - Grant | $0.00 | +61.0K | 169.0K | +56% | $0 | |
| 2021-11-22 | 2021-11-19 | FATE | Chu Yu-Waye | Senior VP Clinical Development | A - Grant | $0.00 | +61.0K | 125.8K | +94% | $0 | |
| 2021-11-22 | 2021-11-19 | FATE | Valamehr Bahram | Chief R, D Off | A - Grant | $0.00 | +61.0K | 156.7K | +64% | $0 | |
| D | 2021-11-22 | 2021-11-18 | FATE | Wolchko J Scott | Pres, CEO, Dir | S - Sale+OE | $54.27 | -20.0K | 393.8K | -5% | -$1.09M |
| D | 2021-11-22 | 2021-11-18 | FATE | Wolchko J Scott | Pres, CEO, Dir | M - OptEx | $2.70 | +20.0K | 413.8K | +5% | +$54.0K |
| D | 2021-11-22 | 2021-11-19 | FATE | Wolchko J Scott | Pres, CEO, Dir | A - Grant | $0.00 | +86.5K | 480.3K | +22% | $0 |
| DM | 2021-10-25 | 2021-10-21+ | FATE | Wolchko J Scott | Pres, CEO, Dir | S - Sale+OE | $59.55 | -60.0K | 393.8K | -13% | -$3.57M |
| DM | 2021-10-25 | 2021-10-21+ | FATE | Wolchko J Scott | Pres, CEO, Dir | M - OptEx | $2.89 | +60.0K | 423.8K | +16% | +$173.6K |
| DM | 2021-10-04 | 2021-10-01 | FATE | TAHL CINDY | GC, Sec | S - Sale+OE | $58.83 | -50.0K | 141.7K | -26% | -$2.94M |
| D | 2021-10-04 | 2021-10-01 | FATE | TAHL CINDY | GC, Sec | M - OptEx | $6.55 | +50.0K | 158.0K | +46% | +$327.5K |
| D | 2021-09-30 | 2021-09-28 | FATE | Dulac Edward J III | CFO | M - OptEx | $35.52 | +17.3K | 71.9K | +32% | +$615.4K |
| D | 2021-09-30 | 2021-09-28 | FATE | Dulac Edward J III | CFO | S - Sale+OE | $62.53 | -19.5K | 52.4K | -27% | -$1.22M |
| D | 2021-09-14 | 2021-09-13 | FATE | Valamehr Bahram | Chief Development Off | M - OptEx | $2.73 | +25.0K | 120.7K | +26% | +$68.2K |
| DM | 2021-09-14 | 2021-09-13 | FATE | Valamehr Bahram | Chief Development Off | S - Sale+OE | $66.29 | -25.0K | 104.9K | -19% | -$1.66M |
| D | 2021-08-20 | 2021-08-19 | FATE | Wolchko J Scott | Pres, CEO, Dir | M - OptEx | $4.84 | +20.0K | 413.8K | +5% | +$96.8K |
| D | 2021-08-20 | 2021-08-19 | FATE | Wolchko J Scott | Pres, CEO, Dir | S - Sale+OE | $88.01 | -20.0K | 393.8K | -5% | -$1.76M |
| M | 2021-08-20 | 2021-08-19 | FATE | Dulac Edward J III | CFO | S - Sale | $88.26 | -3,474 | 54.5K | -6% | -$306.6K |
| D | 2021-08-05 | 2021-08-03 | FATE | Xu Yuan | Dir | A - Grant | $0.00 | +4,744 | 4,744 | New | $0 |
| DM | 2021-07-26 | 2021-07-22+ | FATE | Wolchko J Scott | Pres, CEO, Dir | S - Sale+OE | $85.66 | -60.0K | 417.2K | -13% | -$5.14M |
| DM | 2021-07-26 | 2021-07-22+ | FATE | Wolchko J Scott | Pres, CEO, Dir | M - OptEx | $3.43 | +60.0K | 423.8K | +16% | +$206.0K |
| DM | 2021-07-02 | 2021-07-01 | FATE | TAHL CINDY | GC, Sec | S - Sale+OE | $85.24 | -55.5K | 160.8K | -26% | -$4.73M |
| DM | 2021-07-02 | 2021-07-01 | FATE | TAHL CINDY | GC, Sec | M - OptEx | $5.64 | +55.5K | 163.6K | +51% | +$313.2K |
Purchase Sale Sale after option exercise All abbreviations